GlassScriptPhysician profile
Matthew A Declouet
NPI 1518342310
$5,665.35
in general payments reported to CMS, 2019-2025
25 companies · $2,052 in 2025
The $2,052 reported for 2025 was more than what 92% of Psychiatric/Mental Health (Nurse Practitioner) providers received nationally (typical 2025 total: $257).
See the full distribution for Psychiatric/Mental Health (Nurse Practitioner)
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2021: $475 · 2022: $215 · 2023: $1,027 · 2024: $1,896 · 2025: $2,052.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $4,949 · Education: $26.25.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $4,949.41 |
| Education | $26.25 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Abbvie INC. | $1,195.65 | 2021-2025 | |
| Alkermes, INC. | $938.18 | 2022-2025 | Aristada, Lybalvi, Vivitrol |
| Iti, INC. (D/B/A Intra-Cellular Therapies, INC.) | $454.71 | 2023-2025 | Caplyta |
| Axsome Therapeutics, INC. | $399.88 | 2023-2025 | Auvelity, Sunosi |
| Otsuka America Pharmaceutical, INC. | $347.05 | 2023-2025 | Rexulti, Abilify Asimtufii, Abilify Maintena |
| Takeda Pharmaceuticals U.S.A., INC. | $343.69 | 2021-2025 | Trintellix |
| Tris Pharma INC | $227.31 | 2024-2025 | Dyanavel Xr |
| Vanda Pharmaceuticals INC. | $224.26 | 2024-2025 | Fanapt, Hetlioz |
| Bausch Health US, LLC | $221.99 | 2021-2025 | Aplenzin, Wellbutrin |
| Avanir Pharmaceuticals, INC. | $177.52 | 2021 | |
| Corium, LLC | $176.90 | 2023-2025 | Azstarys |
| E.R. Squibb & Sons, L.L.C. | $168.11 | 2025 | Cobenfy |
| Sunovion Pharmaceuticals INC. | $162.19 | 2021-2022 | |
| Janssen Pharmaceuticals, INC | $111.60 | 2024-2025 | Spravato |
| Almatica Pharma LLC | $94.43 | 2024-2025 | Loreev Xr |
Show all 25 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Neos Therapeutics, LP | $94.27 | 2023-2025 | Adzenys Xr-Odt |
| Neurocrine Biosciences, INC. | $73.93 | 2024-2025 | Ingrezza |
| Supernus Pharmaceuticals, INC. | $57.72 | 2022-2025 | Qelbree, Qelbree |
| Noven Therapeutics, LLC | $53.63 | 2023-2024 | Xelstrym, Secuado |
| Collegium Pharmaceutical, INC. | $32.87 | 2025 | Jornay Pm |
| Braeburn INC. | $29.99 | 2025 | Brixadi |
| Teva Pharmaceuticals USA, INC. | $24.39 | 2023 | Uzedy |
| Ironshore Pharmaceuticals INC. | $20.43 | 2024 | |
| Lundbeck LLC | $19.09 | 2025 | Rexulti |
| Orexo US, INC. | $15.56 | 2021 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Matthew Declouet listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.